NCI-2024-04758

A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SNS-101 (anti-VISTA) as Monotherapy and in Combination with Cemiplimab in Patients with Advanced Solid Tumors

This Phase 1/2 open-label study aims to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101 (an anti-VISTA therapy) as monotherapy and in combination with cemiplimab (a PD-1 inhibitor) in patients with advanced solid tumors. SNS-101 targets VISTA, a checkpoint protein that can suppress immune responses against cancer cells. Inhibiting VISTA aims to enhance the body's immune system to fight cancer. Evaluating SNS-101 in combination with cemiplimab leverages the potential synergies between inhibiting VISTA and blocking PD-1, potentially leading to more effective treatment outcomes.

open-label: Los pacientes saben qué tratamientos se les están administrando

advanced: Advanced cancer means that the cancer cells from the original tumor (primary tumor) get loose, spread by traveling through the body, and start a new tumor (metastatic tumor) somewhere else in the body.

pharmacokinetics: Pharmacokinetics studies how medicines move around in the body, including how they are absorbed, distributed, broken down, and removed.

pharmacodynamics: Study of how a drug affects the body, how it works, its effects, and how it interacts with its target

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT05864144

Clinical Trial Site: Sinai

To see all available clinical trials click here.